Skip to content

Ramiro Solis

2 papers in the library · publishing 2026

Papers

A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity

Zenodo (CERN European Organization for Nuclear Research) June 24, 2026 Ramiro Solis

The brain's ability to rewire itself declines with age, but why remains unclear. This paper examines whether the compound N,N-dimethyltryptamine (DMT) helps maintain neuroplasticity, and whether its decline contributes to age-related loss of cognitive flexibility. DMT promotes synaptic growth and neurogenesis in animals, and levels are reportedly highest during development. However, evidence is mixed: one study finds DMT concentrations comparable to serotonin, while another finds it undetectable in rat brain. DMT's affinity for the sigma-1 receptor is three orders of magnitude higher than physiological concentrations, and a key finding about intracellular 5-HT2A receptor binding has not been replicated. The paper does not claim the hypothesis is established, but proposes a research program to test whether DMT depletion causes lost plasticity or is incidental.

A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions

Zenodo (CERN European Organization for Nuclear Research) June 22, 2026 Ramiro Solis

The human body has enzymes that both make and rapidly break down DMT, a molecule structurally nearly identical to serotonin that binds to the same serotonin receptors. This raises the question of whether DMT serves an endogenous physiological function or is merely a metabolic byproduct. Evidence is mixed: one report finds DMT concentrations in the nanomolar range comparable to serotonin and dopamine, while another finds DMT undetectable in rat brain. DMT's affinity for the sigma-1 receptor is far weaker than its likely physiological concentrations, and a key finding about intracellular 5-HT2A receptor binding has not been replicated.